Purespring Therapeutics

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. Purespring Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $81.6 million. It has raised $165 million.

Last price · $/share

—

Implied valuation

$81.6M

Total raised

$164.7M

Last round

—

How much has Purespring Therapeutics raised?

$164.7Macross 0 recorded rounds

Free account

More of Purespring Therapeutics with a free account

·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Purespring Therapeutics investors

6 investors are on record for Purespring Therapeutics, including British Business Bank, Sofinnova Partners, Forbion and Gilde Healthcare.

For fundraisers

Raising for a company like Purespring Therapeutics?

6 investors have backed Purespring Therapeutics.

See all 6 investors →

Frequently asked about Purespring Therapeutics

How much has Purespring Therapeutics raised?: Purespring Therapeutics has raised $164.7M in total across 0 recorded funding rounds.